Nektar Therapeutics (NKTR) Expected to Post Earnings of -$0.71 Per Share

Share on StockTwits

Wall Street brokerages forecast that Nektar Therapeutics (NASDAQ:NKTR) will post ($0.71) earnings per share for the current fiscal quarter, Zacks reports. Six analysts have provided estimates for Nektar Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.62) and the lowest estimate coming in at ($0.82). Nektar Therapeutics reported earnings per share of ($0.60) during the same quarter last year, which suggests a negative year-over-year growth rate of 18.3%. The company is scheduled to issue its next earnings report on Thursday, May 9th.

According to Zacks, analysts expect that Nektar Therapeutics will report full-year earnings of ($3.02) per share for the current financial year, with EPS estimates ranging from ($3.28) to ($2.49). For the next financial year, analysts forecast that the company will report earnings of ($2.74) per share, with EPS estimates ranging from ($3.93) to ($1.32). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that follow Nektar Therapeutics.

Nektar Therapeutics (NASDAQ:NKTR) last issued its quarterly earnings results on Thursday, February 28th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.13. Nektar Therapeutics had a net margin of 57.09% and a return on equity of 50.22%. During the same quarter last year, the firm earned ($0.21) EPS.

A number of equities analysts have recently commented on NKTR shares. Goldman Sachs Group started coverage on shares of Nektar Therapeutics in a report on Thursday, December 13th. They set a “buy” rating and a $62.00 price target on the stock. Zacks Investment Research upgraded shares of Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $41.00 price target on the stock in a report on Tuesday, December 11th. Mizuho reiterated a “buy” rating and set a $81.00 price target on shares of Nektar Therapeutics in a report on Wednesday, January 23rd. Piper Jaffray Companies set a $100.00 price target on shares of Nektar Therapeutics and gave the stock a “buy” rating in a report on Friday, March 1st. Finally, TheStreet upgraded shares of Nektar Therapeutics from a “d+” rating to a “c” rating in a report on Thursday, February 28th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and ten have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $73.92.

In related news, SVP Jillian B. Thomsen sold 16,119 shares of the business’s stock in a transaction on Monday, February 4th. The shares were sold at an average price of $42.16, for a total value of $679,577.04. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO John Nicholson sold 63,000 shares of the business’s stock in a transaction on Monday, January 28th. The shares were sold at an average price of $42.82, for a total transaction of $2,697,660.00. Following the completion of the transaction, the chief operating officer now owns 237,477 shares in the company, valued at approximately $10,168,765.14. The disclosure for this sale can be found here. In the last 90 days, insiders sold 241,824 shares of company stock worth $10,249,993. 4.31% of the stock is owned by company insiders.

A number of hedge funds have recently added to or reduced their stakes in the stock. Norges Bank bought a new stake in Nektar Therapeutics in the fourth quarter valued at $63,723,000. Burleson & Company LLC increased its stake in Nektar Therapeutics by 7.6% in the fourth quarter. Burleson & Company LLC now owns 7,098 shares of the biopharmaceutical company’s stock valued at $286,000 after purchasing an additional 500 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Nektar Therapeutics by 82.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 408,526 shares of the biopharmaceutical company’s stock valued at $13,433,000 after purchasing an additional 184,055 shares in the last quarter. FMR LLC increased its stake in Nektar Therapeutics by 8.5% in the fourth quarter. FMR LLC now owns 25,961,520 shares of the biopharmaceutical company’s stock valued at $853,355,000 after purchasing an additional 2,041,954 shares in the last quarter. Finally, Kentucky Retirement Systems bought a new stake in Nektar Therapeutics in the fourth quarter valued at $247,000. Institutional investors and hedge funds own 93.35% of the company’s stock.

Shares of NASDAQ:NKTR opened at $33.48 on Tuesday. The firm has a market cap of $5.99 billion, a PE ratio of 8.86 and a beta of 3.09. The company has a current ratio of 17.53, a quick ratio of 17.39 and a debt-to-equity ratio of 0.14. Nektar Therapeutics has a 52 week low of $29.22 and a 52 week high of $108.23.

About Nektar Therapeutics

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

Recommended Story: Is it Safe to Invest in Commodities?

Get a free copy of the Zacks research report on Nektar Therapeutics (NKTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

$1.37 Billion in Sales Expected for Caci International Inc  This Quarter
$1.37 Billion in Sales Expected for Caci International Inc This Quarter
TokenStars Trading 26.8% Higher  This Week
TokenStars Trading 26.8% Higher This Week
Akoustis Technologies Inc  Expected to Post Earnings of -$0.25 Per Share
Akoustis Technologies Inc Expected to Post Earnings of -$0.25 Per Share
Selfkey  24-Hour Trading Volume Hits $967,433.00
Selfkey 24-Hour Trading Volume Hits $967,433.00
$2.80 Billion in Sales Expected for Royal Caribbean Cruises Ltd  This Quarter
$2.80 Billion in Sales Expected for Royal Caribbean Cruises Ltd This Quarter
Waves Community Token Trading 1.3% Higher  Over Last Week
Waves Community Token Trading 1.3% Higher Over Last Week


© 2006-2019 Ticker Report